Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.
3D microtissues
MPNST
NF1
PDX
drug screening
genomic variants
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
medline:
8
11
2023
pubmed:
29
5
2023
entrez:
29
5
2023
Statut:
ppublish
Résumé
Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas that often develop in patients with neurofibromatosis type 1 (NF1). To address the critical need for novel therapeutics in MPNST, we aimed to establish an ex vivo 3D platform that accurately captured the genomic diversity of MPNST and could be utilized in a medium-throughput manner for drug screening studies to be validated in vivo using patient-derived xenografts (PDX). Genomic analysis was performed on all PDX-tumor pairs. Selected PDX were harvested for assembly into 3D microtissues. Based on prior work in our labs, we evaluated drugs (trabectedin, olaparib, and mirdametinib) ex vivo and in vivo. For 3D microtissue studies, cell viability was the endpoint as assessed by Zeiss Axio Observer. For PDX drug studies, tumor volume was measured twice weekly. Bulk RNA sequencing was performed to identify pathways enriched in cells. We developed 13 NF1-associated MPNST-PDX and identified mutations or structural abnormalities in NF1 (100%), SUZ12 (85%), EED (15%), TP53 (15%), CDKN2A (85%), and chromosome 8 gain (77%). We successfully assembled PDX into 3D microtissues, categorized as robust (>90% viability at 48 h), good (>50%), or unusable (<50%). We evaluated drug response to "robust" or "good" microtissues, namely MN-2, JH-2-002, JH-2-079-c, and WU-225. Drug response ex vivo predicted drug response in vivo, and enhanced drug effects were observed in select models. These data support the successful establishment of a novel 3D platform for drug discovery and MPNST biology exploration in a system representative of the human condition.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas that often develop in patients with neurofibromatosis type 1 (NF1). To address the critical need for novel therapeutics in MPNST, we aimed to establish an ex vivo 3D platform that accurately captured the genomic diversity of MPNST and could be utilized in a medium-throughput manner for drug screening studies to be validated in vivo using patient-derived xenografts (PDX).
METHODS
METHODS
Genomic analysis was performed on all PDX-tumor pairs. Selected PDX were harvested for assembly into 3D microtissues. Based on prior work in our labs, we evaluated drugs (trabectedin, olaparib, and mirdametinib) ex vivo and in vivo. For 3D microtissue studies, cell viability was the endpoint as assessed by Zeiss Axio Observer. For PDX drug studies, tumor volume was measured twice weekly. Bulk RNA sequencing was performed to identify pathways enriched in cells.
RESULTS
RESULTS
We developed 13 NF1-associated MPNST-PDX and identified mutations or structural abnormalities in NF1 (100%), SUZ12 (85%), EED (15%), TP53 (15%), CDKN2A (85%), and chromosome 8 gain (77%). We successfully assembled PDX into 3D microtissues, categorized as robust (>90% viability at 48 h), good (>50%), or unusable (<50%). We evaluated drug response to "robust" or "good" microtissues, namely MN-2, JH-2-002, JH-2-079-c, and WU-225. Drug response ex vivo predicted drug response in vivo, and enhanced drug effects were observed in select models.
CONCLUSIONS
CONCLUSIONS
These data support the successful establishment of a novel 3D platform for drug discovery and MPNST biology exploration in a system representative of the human condition.
Identifiants
pubmed: 37246765
pii: 7184182
doi: 10.1093/neuonc/noad097
pmc: PMC10628938
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2044-2057Subventions
Organisme : NCI NIH HHS
ID : UH3 CA244687
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Références
EMBO Mol Med. 2018 Dec;10(12):
pubmed: 30389682
Acta Biomater. 2017 Jul 15;57:47-58
pubmed: 28483691
Cancer Cell. 2008 Feb;13(2):117-28
pubmed: 18242512
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Cancer. 1998 Jun 1;82(11):2191-203
pubmed: 9610699
Cell Rep. 2013 Sep 26;4(6):1116-30
pubmed: 24055055
Cell. 2008 Oct 31;135(3):437-48
pubmed: 18984156
Neuro Oncol. 2019 Aug 5;21(8):981-992
pubmed: 30722027
Sci Data. 2020 Jun 19;7(1):184
pubmed: 32561749
Neurooncol Adv. 2021 Sep 10;3(1):vdab129
pubmed: 34647023
Genes (Basel). 2020 Apr 28;11(5):
pubmed: 32353955
Biomed Res Int. 2020 Apr 13;2020:6051210
pubmed: 32352002
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 29117388
Commun Biol. 2020 Jul 9;3(1):367
pubmed: 32647357
Cancer Res. 2014 Apr 15;74(8):2340-50
pubmed: 24576830
Neurooncol Adv. 2019 Nov 14;2(Suppl 1):i40-i49
pubmed: 32642731
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Br J Clin Pharmacol. 2009 Sep;68(3):320-1
pubmed: 19740389
Tissue Eng Part C Methods. 2019 Jan;25(1):25-36
pubmed: 30430922
Mol Cancer Ther. 2022 Jul 5;21(7):1246-1258
pubmed: 35511749
Cancer Cell Int. 2020 Feb 19;20:58
pubmed: 32099531
Cells. 2019 May 06;8(5):
pubmed: 31064068
Nat Genet. 2014 Nov;46(11):1227-32
pubmed: 25240281
Integr Biol (Camb). 2018 Sep 17;10(9):555-565
pubmed: 30140833
Am Surg. 2014 Sep;80(9):873-7
pubmed: 25197873
Nat Rev Mol Cell Biol. 2020 Oct;21(10):571-584
pubmed: 32636524
Cancer Res. 2012 Jul 1;72(13):3405-13
pubmed: 22700876
Oncotarget. 2017 Nov 17;8(64):107423-107440
pubmed: 29296175
Sci Data. 2017 Apr 11;4:170045
pubmed: 28398289
Sarcoma. 2019 Jul 24;2019:7656747
pubmed: 31427883
Int J Cancer. 2010 Nov 15;127(10):2292-9
pubmed: 20162577
J Natl Compr Canc Netw. 2018 Aug;16(8):967-974
pubmed: 30099373
Cancer Discov. 2023 Mar 1;13(3):654-671
pubmed: 36598417
Mol Cancer Ther. 2013 Sep;12(9):1906-17
pubmed: 23858101
Science. 1999 Dec 10;286(5447):2172-6
pubmed: 10591652
Int J Mol Sci. 2021 Nov 19;22(22):
pubmed: 34830355
JCI Insight. 2021 Mar 22;6(6):
pubmed: 33591953
Cell. 2021 Dec 9;184(25):6119-6137.e26
pubmed: 34890551
iScience. 2023 Jan 31;26(2):106096
pubmed: 36818284
Small GTPases. 2020 Mar;11(2):77-85
pubmed: 28981399
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Sci Data. 2019 Dec 13;6(1):319
pubmed: 31836719
Cancer Res. 2002 Aug 1;62(15):4507-13
pubmed: 12154062
Nat Genet. 2013 Jul;45(7):756-66
pubmed: 23685747
Cancers (Basel). 2021 Mar 30;13(7):
pubmed: 33808166